ArticleTherapeutic advances in drug safety2023
Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.
Article in Therapeutic advances in drug safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Heterogeneity in adverse events associated with lumateperone: a study on potential subgroup-specific differences.The international journal of neuropsychopharmacology · 2026Article
- Neoplasm Adverse Events Associated With Anti-Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study.Cancer medicine · 2026Article
- Adverse events associated with tirzepatide: a focus on subgroup-specific differences.BMC pharmacology & toxicology · 2026Article
- Potential heterogeneity of epcoritamab associated adverse events in demographics and dosing regimens.Frontiers in medicine · 2026Article
- Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025).Healthcare (Basel, Switzerland) · 2025Article
- Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system.BMC pharmacology & toxicology · 2025Article
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Statin use and the risk of tubulointerstitial nephritis: a real-world signal detection analysis using FDA Adverse Event Reporting System.Frontiers in medicine · 2025Article
- Proton pump inhibitors-induced thrombocytopenia: A systematic literature analysis of case reports.Open medicine (Warsaw, Poland) · 2025Article
- Exploration of adverse event profiles for glofitamab: A disproportionality analysis using the FDA adverse event reporting system.PloS one · 2025Article
- Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database.BMC cancer · 2024Article
- Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.The journal of headache and pain · 2024Article
- A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib.Scientific reports · 2024Article
- A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime.Therapeutic advances in drug safety · 2024Article
- Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk ofAntibiotics (Basel, Switzerland) · 2023Article
- Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This research aims to explore and compare the signals of rhabdomyolysis from the use of Proton pump inhibitors (PPIs) using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods: Rhabdomyolysis and related terms submitted between 2013 and 2021 were retrieved from the FAERS database. The data were analyzed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Empirical Bayes Geometric Mean (EBGM) and the information component (IC). The signals of rhabdomyolysis associated with PPIs use were detected in both 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) utilizers and non-utilizers. Results: A total of 7,963,090 reports were retrieved and analyzed. Fifty-seven reports linked PPIs to rhabdomyolysis out of 3670 reports from other drugs (non-statin included). The association of rhabdomyolysis and PPIs was significant in both statins included, and non-statin-included reports, although with varying degrees of association. The ROR was 2.5 (95% confidence interval [CI] 1.9-3.2) for PPIs in non-statin-included reports and 2 (95% CI: 1.5-2.6) for PPIs in statin-included reports. Conclusion: Significant signals of rhabdomyolysis were associated with PPIs. However, its signals were higher in non-statin-included reports compared to statin-included reports. Plain Language Summary:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.